Matthew K. Fust - 13 Jul 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Director
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 13 Jul 2022
Net transactions value: -$111,190
Form type: 4
Filing time: 15 Jul 2022, 16:30:47 UTC
Previous filing: 28 Jun 2022
Next filing: 02 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$8,265	+5,700	+45%	$1.45^*	18,236	13 Jul 2022	Direct	F1
transaction	CRNX	Common Stock	Sale	$119,455	-5,700	-31%	$20.96	12,536	13 Jul 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Non-qualified stock option (Right to Buy)	Options Exercise	$0	-5,700	-100%	$0.000000^*	0	13 Jul 2022	Common stock	5,700	$1.45	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of November 6, 2017.